JUN 08, 2020 3:02 PM PDT

Using Soft Tissue Sarcoma's Immune Defense as a Biomarker

WRITTEN BY: Jasper Cantrell

Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD-1 is a receptor on the cell membrane that promotes cellular apoptosis, or cell death, in T-cells. It also prevents apoptosis in regulatory T-cells, which usually suppresses the immune response. Programmed death-ligand 1 (PD-L1) Is the trigger factor that initiates PD-1 signaling. Many cancers overexpress PD-L1, which creates an immunosuppressive environment and protects the tumor from the innate anti-cancer immune response. PD-1 inhibitors have had success in preventing this, promoting anti-cancer activity through the innate immune response.

Although these interactions are well studied in many cancer types, this not the case for soft tissue sarcomas (STSs). STSs are rare malignant neoplasms, with as many as 40% of patients seeing metastatic recurrence post-operation. A team from the Mie University School of Medicine in Japan hypothesized that the blood soluble PD-L1 (sPD-L1) would create an immunosuppressive environment around STS tumors and could be used as a prognostic biomarker in STS treatment.

Using data from 135 STS patients enrolled in the program at the university, the team began their analysis. The first observation they made was that compared to healthy volunteers, STS, and benign tumor patients had increased PD-L1 levels overall. Benign and STS tumors did not have a significant difference in sPD-L1 levels, however. Late-stage STS patients who developed metastasis, as well as those who unfortunately passed, were observed to have higher sPD-L1 concentrations than the rest of the patient group. Statistical analysis confirmed the correlation of high sPD-L1 levels and a low metastatic-free survival and overall-survival rate in patients with late-stage STSs.

The results of this study were not the clearest support of sPD-L1 and STS prognosis. Late-stage STS patients were the only patients with a clear correlation between sPD-L1 levels and overall survival rates or metastasis-free survival rates. The team admits to the limitations of the relatively small patient group, with possible bias from the large number of late-stage STSs. The type of STSs ranged across twenty sub-types as well, possibly clouding the data. Even with these limitations, the results show that sPD-L1 may be a useful biomarker for late-stage STS prognosis, and further study might reveal even more uses.

Sources: Nature, ImmunoOncology

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 03, 2020
Cancer
Using Machine Learning to Further Classify Triple-Negative Breast Cancer
JUL 03, 2020
Using Machine Learning to Further Classify Triple-Negative Breast Cancer
One of the challenges of facing cancer researchers is coming up with a clearly defined classification system. Cancer is ...
JUL 04, 2020
Cancer
New mechanism that supports the progression and relapse cancer discovered
JUL 04, 2020
New mechanism that supports the progression and relapse cancer discovered
Researchers have found a mechanism of a key protein that supports the progression and relapse of cancer. This discovery ...
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
JUL 27, 2020
Cancer
Identifying Tumor Cells in the Blood with Artificial Intelligence
JUL 27, 2020
Identifying Tumor Cells in the Blood with Artificial Intelligence
Cancer diagnostics is an area of keen interest in the fight against cancer. Cancer often slips by routine checkups and v ...
JUL 27, 2020
Genetics & Genomics
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
JUL 27, 2020
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
A new computational tool was created by scientists at CHOP and it has now revealed new mutations that are linked to five ...
JUL 28, 2020
Cancer
Should you get your DNA test for community-based genetic screening?
JUL 28, 2020
Should you get your DNA test for community-based genetic screening?
In a new study published in the journal Nature Medicine, researchers champion the potential of community-based gene ...
Loading Comments...